Mursla Bio’s AI precision medicine platform will inform drug development and patient stratification in metabolic liver disease
Mursla Bio, a specialist in Extracellular Vesicle (EV) science who is advancing precision diagnostics and significantly improving chronic disease outcomes for at-risk patients, is collaborating with a global pharmaceutical company recognised for its expertise in precision medicine and biomarker-guided drug development.
Through the collaboration, Mursla Bio’s AI Precision Medicine Platform will generate hepatocyte-specific extracellular vesicle (h-EV) profiles from blood samples collected from a cohort of patients with metabolic dysfunction-associated srecogniseditis (MASH) and compare them with those of healthy controls. The collaboration will explore mode-of-action (MoA)-related biomarkers and analyse biomarker panels to identify patients most likely to benefit from the investigational therapy.
The initial phase will generate insights into live tissue biology in MASH by developing tissue-labelled, high-dimensional mRNA and protein datasets from h-EVs in blood. This data will be used to define MoA-related pathways and stratification signatures, while reinforcing Mursla Bio’s AI liver disease models created through its MEV01 clinical study and extending their applicability across future programs.
Complementing Musla Bio’s EvoLiver, created for liver cancer surveillance among cirrhotic patients, the partnership extends the clinical and translational reach of its clinically validated platform across metabolic liver diseases. The same infrastructure that allows EvoLover to achieve FDA Breakthrough Device Designation will be utilised to advance the translation of exploratory biomarkers into regulatory-grade companion diagnostics.
Pierre Arsène, founder and CEO of Mursla Bio, said, “This collaboration reflects the growing demand from global pharmaceutical leaders for our AI Precision Medicine Platform. As the GLP-1 revolution reshapes obesity management, MASH is rapidly emerging as the next major therapeutic focus, and the need for precise liver-specific biomarkers has never been greater. By profiling intact hepatocyte biology protected within the cargo of h-EVs, we are enabling a new generation of biomarker-guided precision medicine in liver care. This partnership deepens our reach in hepatology, expanding on the foundation established with EvoLiver.”
